JP Patent

JP6894952B2 — 癌治療のためのｐｄ−１拮抗薬およびｖｅｇｆｒ阻害剤の組み合わせ

Assigned to Merck Sharp and Dohme LLC · Expires 2021-06-30 · 5y expired

What this patent protects

Patent listed against Inlyta.

Drugs covered by this patent

Patent Metadata

Patent number
JP6894952B2
Jurisdiction
JP
Classification
—
Expires
2021-06-30
Drug substance claim
No
Drug product claim
No
Assignee
Merck Sharp and Dohme LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.